VascuWave™ Technology Is A Non-Invasive & Pain Free Solution For ED

Just $2,995 with free & discrete shipping

Call now to see if you qualify for special pricing!

45 Day Money Back Guarantee & 2 Year Warranty

If You Are Not 100% Satisfied We Will Refund Your Money Back

All returns must have their original packing

  • Non-Invasive Procedure: Traditional solutions for Erectile Dysfunction can be invasive and risk side-effects. Our solution is non-invasive and safe.
  • In-Home Solution: Our handheld device provides patients with the ability to independently administer the procedure in the privacy of their own home.
  • Long Term Solution For ED: This device is effective in anatomically rejuvenating tissue, vessels, and encouraging blood flow.
  • Acoustic Wave: Acoustic Wave Technology helps encourage tissue rejuvenation and vascular growth.
  • Approval Required: This device is so effective that it requires approval by a medical professional for use.
  • Phone-in Support: We provide access to support for your device as well as how-to consultations.

Call 833-477-4376 Now And Speak To One Of Our Patient Care Specialists!

Why VascuWave™?

VascuWave™ Technology is a revolutionary procedure for erectile dysfunction, Peyronie’s disease, & prostatitis. This revolutionary device allows for patients to self administer the procedure in their own home. VascuWave Technology is based on proven scientific studies and peer reviews. It’s a non-invasive solution for erectile dysfunction, Peyronie’s disease, & prostatitis, utilizing an FDA Cleared device. 

BENEFITSVascuWave™ TechnologyCompetitor OneCompetitor TwoP-shot (PRP)Meds (Viagra, Cialis, Staxyn)Injections (TriMix, BiMix, QuadMix)
No Medication✔✔✔✔
Benefits last up to 2 years✔✔✔✔
Treats Peyonie’s Disease✔✔✔✔
Treats Abacterial Prostatitis✔No ProtocolVariety of Protocols
Non-invasive✔✔✔✔
No major side effects✔✔✔✔
Improves Sensitivity✔✔✔
Physician Prescribed Device✔
Physician Standardized Protocol and Equipment✔✔
Hand-Held Device✔
In-Home Use✔
Over 75% Success rate✔✔✔
Money Back Guarantee✔✔
Economical✔
Erectile Benefit Score Max Score 151577511

VascuWave™ Solutions!

VascuWave™

Erectile Dysfunction

VascuWave™ is the first prescription device directly available to the consumer that utilizes proven technology to safely and comfortably improve erectile function, augment sexual performance in all men regardless of age, and reverse the underlying cause of erectile dysfunction by improving blood flow to the penis by repairing aged blood vessels and creating new ones. Furthermore, acoustic wave procedure stimulates the growth of new nerves within the penis thereby further enhancing sensation and sexual function. VascuWave™ utilizes a proven protocol adapted by world renowned physicians Dr. Dattoli and Dr. Kaminski. Acoustic wave technology is based upon over 45 studies showing greater than 75% success rate in treating erectile dysfunction including randomized trials and meta-analyses. 75% of all men receiving the VascuWave™ technology have reported improved sexual function and no longer require oral ED medications. VascuWave™ utilizes an FDA Cleared procedure.

Peyronie’s Disease

VascuWave™ technology is an effective in-home procedure for Peyronie’s disease (penile deformity and curvature with associated painful erections) it breaks down scar tissue, decreasing or eliminating the pain, and enhancing erectile function.

Prostatitis (Chronic Abacterial)/Chronic Pelvic Pain Syndrome

VascuWave™ technology is the only in-home device which has demonstrated efficacy in the most common form of prostatitis, chronic nonbacterial prostatitis/chronic pelvic pain syndrome. 90% of prostatitis cases are due to this form. Symptoms include pain (genital, pelvic, and abdominal), erectile dysfunction, and urinary symptoms. Antibiotics are ineffective. VascuWave™ technology has been shown to reduce pain and erectile dysfunction.

Sexual Enhancement for Men with Normal Sexual Function

VascuWave™ is the 1st and only in-home prescription device that is drug-free, safe, and non-invasive. VascuWave™ technology is a perfect solution for men who desire to augment their erectile function, have longer stamina, and faster restoration after orgasm (decreased recovery time between orgasms).  ED medications such as Cialis, Viagra, Levitra, or Staxyn should not be used for recreational use and can cause addiction and physical side effects.

Michael J. Dattoli, MD

Co-Founder 

Michael J. Dattoli, MD, is a board-certified radiation oncologist with well over two decades of brachytherapy experience and has performed thousands of prostate implant procedures. He is considered the foremost pioneer optimizing brachytherapy designs to maximize tumor eradication and minimize symptoms. Dr. Dattoli has successfully applied the same technology to other forms of cancer, including breast, head and neck, GI, GYN, sarcomas and lung malignancies. He is a noted author and speaker in this complex field of medicine. Dr. Dattoli attended the University of California at Berkeley and was the Valedictorian of his class at Vassar College; he earned his medical degree at Mount Sinai School of Medicine, Radiation Oncology at New York University Medical Center, then distinguished himself at Memorial Sloan-Kettering Cancer Center and New York Hospital-Cornell University Medical Center, as the Special Fellow in Brachytherapy. He was appointed Associate Professor in Brachytherapy and Radiation Oncology at Memorial Sloan- Kettering Cancer Center in New York and at New York Hospital-Cornell University Medical Center prior to relocating to Florida. Dr. Dattoli serves on multiple journal editorial review boards. Government appointments include “The Prostate Cancer Task Force” in Florida and consultant to the “Washington Oncology Roundtable Advisory Committee”. He was selected by the International Association of Oncologists as a Leading Physician of the World and top Brachytherapist.

Joseph M. Kaminski, MD

Co-Founder

Joseph M. Kaminski, MD, previously Senior Medical Staff at the National Cancer Institute at the National Institutes of Health, is a board certified Radiation Oncologist who is internationally known for his work in accelerating the development of cancer therapeutics including normal tissue radioprotectors/mitigators, imaging techniques, and important interventional devices. He has authored more than 70 publications in peer reviewed journals and has served on multiple journal editorial boards. Dr. Kaminski has also held positions as a Lead Medical Officer at the Food and Drug Administration and a medical officer at the National Institutes of Allergy and Infectious Diseases. He graduated with highest honors from Georgia Institute of Technology, one of the nation’s top bioengineering universities, and completed medical school at the Medical College of Georgia. Dr. Kaminski was a resident in Nuclear Medicine and Radiation Oncology at Vanderbilt University Medical Center (Nashville, TN), and also in Radiation Oncology at the prestigious Fox Chase Cancer Center (Philadelphia, PA). He comes to the Sarasota Center from his recent post at Georgia Regents University where he served as the Co-Leader of the Neurological Oncology Multidisciplinary Program for the Cancer Center and the Director of Genitourinary (e.g., prostate), Gastrointestinal, and Central Nervous System Radiation Programs.

Stanislav Emelianov PhD

Scientific Advisor 

Dr. Stanislav Emelianov is a Joseph M. Pettit Endowed Chair, Georgia Research Alliance Eminent Scholar, and Professor of Electrical & Computer Engineering and Biomedical Engineering at the Georgia Institute of Technology. He is also appointed at Emory University School of Medicine where he is Professor of Radiology and is affiliated with Emory’s Winship Cancer Institute and other clinical units. Furthermore, Dr. Emelianov is Director of the Ultrasound Imaging and Therapeutics Research Laboratory at the Georgia Institute of Technology. Dr. Emelianov is an internationally recognized expert in biomedical imaging instrumentation and nanoagents for imaging and therapy. He is the author of over 500 publications including peer-reviewed research articles, invited reviews, book chapters, conference proceedings, and patents. In recognition of his contributions to the field, Dr. Emelianov was elected to the College of Fellows of the American Institute for Medical and Biological Engineering. He is past Vice-President for Ultrasonics of the IEEE Ultrasonics, Ferroelectrics and Frequency Control Society, and senior member of several professional organizations.

JM - Vascuwave

Jeffrey Mechanick, MD

Scientific Advisor 

Dr. Mechanick is Professor of Medicine and Medical Director of the Marie-Josee and Henry R.Kravis Center for Cardiovascular Health at Mount Sinai Heart, and in the Cardiovascular Institute and Division of Cardiology, and Director of Metabolic Support in the Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai.  He received his M.D. degree from the Icahn School of Medicine at Mount Sinai, completed Internal Medicine residency at Baylor College of Medicine, and completed Endocrine Fellowship at The Mount Sinai Hospital.  Dr. Mechanick authored over 300 publications in Endocrinology, Metabolism, and Nutrition Support.  He is the 2016-2017 President of the American College of Endocrinology, 2013-2014 Past President of the American Association of Clinical Endocrinologists, and 2005-2006 Past President of the American Board of Physician Nutrition Specialists. Dr. Mechanick co-edited Nutritional Strategies for theDiabetic and Prediabetic Patient, Power of Prevention: The Complete Guide to Lifelong NutritionThyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines, Molecular Nutrition – The Practical Guide, and Lifestyle Medicine – A Manual for Clinical Practice, andco-authored Diabetes Mellitus Pocket and Nutritional Medicine Pocket.  Dr. Mechanick was appointed as a member of the President’s Council on Fitness, Sports and Nutrition (PCFSN) Science Board for 2010-2013 and was the 2013-2015 Editor-in-Chief and currently Editor-in-Chief Emeritus of the PCFSN quarterly publication Elevate Health.  Dr. Mechanick also chairs the International Transcultural Diabetes Nutrition Algorithm Working Group. Dr. Mechanick currently serves as Chair of the Board of Visitors for the College of Computer, Mathematics, and Natural Sciences at the University of Maryland at College Park and was also the 2011 recipient of the University of Maryland Industry Impact Award and the Biology Alumnus Award.  Dr. Mechanick’s research interests are in the fields of nutrition and metabolic support, obesity and lifestyle medicine, and network analysis of complex systems. Dr. Mechanick is responsible for training cardiology and endocrine fellows at Mount Sinai in lifestyle medicine, nutrition, and metabolic support. Certified in Endocrinology by the American Board of Internal Medicine.

Orhan H. Suleiman, MS, PhD, FAAPM, FHPS

Orhan H. Suleiman, MS, PhD, FAAPM, FHPS

Scientific Advisor 

Orhan H. Suleiman, MS, PhD, FAAPM, FHPS, has expertise encompassing a broad range of scientific and regulatory experience related to Food and Drug Administration (FDA) regulated medical products (drugs, medical devices, and biologics). He retired in November, 2014, from the United States FDA, after 37 years with the federal agency responsible for assuring the safety and efficacy of such products.  At FDA he was the Senior Science Policy Advisor in the Office of New Drugs, where he was involved in many regulatory initiatives involving safety, human subject research, and inspections.  He represented the FDA on a variety of domestic and international committees. He received his BS (1970) and MS (1972) degrees in Radiological Sciences from the University of Florida, and his Ph.D. (1989) from the Johns Hopkins School of Hygiene and Public Health.  In 1998 he was appointed into FDA’s Senior Biomedical Research Service (SBRS), a select group of federal senior level scientists.  In 1999 he was elected as a Fellow of the American Association of Physicists in Medicine (AAPM), served as president of the Baltimore Washington Chapter of the Health Physics Society (2006-7), and in 2013 he was also selected as a Fellow in the Health Physics Society.  He is an Emeritus member of these societies as well as the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He has authored over 50 formal publications in the scientific literature, and presented numerous times domestically and internationally on these topics.